Antibiotic prophylaxis in obese patients submitted to bariatric surgery. A systematic review

Acta Cirurgica Brasileira

Volumn 29, Issue 3, 2014, Pages 209-217

  Fischer, Maria Isabel ^a   Dias, Cícero ^b   Stein, Airtontetelbom ^c   Meinhardt, Nelson Guardiola ^d   Heineck, Isabela ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d Hospital Conceicao   (Brazil)

Author keywords

Antibiotic prophylaxis; Bariatric surgery; Cefazolin; Obesity; Review

Indexed keywords

CEFAZOLIN; CEFOXITIN; PLACEBO; TIMENTIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BARIATRIC SURGERY; BODY MASS; DATA BASE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH BYPASS; SURGICAL INFECTION; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BARIATRIC SURGERY; CEFAZOLIN; CLINICAL TRIALS AS TOPIC; HUMANS; OBESITY; OBSERVATIONAL STUDY AS TOPIC; RISK FACTORS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 84896828293     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502014000300010     Document Type: Article

References (20)

1. World Health Organization. Global database on body mass index 2012 [26 Oct 2012]. Available from: http://apps.who.int/bmi/index.jsp.
2. Padwal R, Klarenbach S, Wiebe N, Birch D, Karmali S, Manns B, Hazel M, Sharma AM, Tonelli M. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. Obes Rev. 2011;12(8):602-621.
3. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431-1437.
4. Chopra T, Zhao JJ, Alangaden G, Wood MH, Kaye KS. Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):317-328.
5. Christou NV, Jarand J, Sylvestre JL, McLean AP. Analysis of the incidence and risk factors for wound infections in open bariatric surgery. Obes Surg. 2004;14(1):16-22.
6. Santos LM, de Oliveira IV, Peters LR, Conde WL. Trends in morbid obesity and in bariatric surgeries covered by the Brazilian public health system. Obes Surg. 2010;20(7):943-948.
7. Freeman IT, Anderson DJ, Hartwig MG, Sexton DJ. Surgical site infections following bariatric surgery in community hospitals: A weighty concern? Obes Surg. 2011;21(7):836-840.
8. van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, van Ramshorst B, Vlaminckx B, Deneer VH, Knibbe CA. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67(10):985-992.
9. Chopra T, Marchaim D, Lynch Y, Kosmidis C, Zhao JJ, Dhar S, Gheyara N, Turner D, Gulish D, Wood M, Alangaden G, Kaye KS. Epidemiology and outcomes associated with surgical site infection following bariatric surgery. Am J Infect Control. 2012;40(9):815-819.
10. Alexander JW, Rahn R, Goodman HR. Prevention of surgical site infections by an infusion of topical antibiotics in morbidly obese patients. Surg Infect (Larchmt). 2009;10(1):53-57.
11. Pories WJ, van Rij AM, Burlingham BT, Fulghum RS, Meelheim D. Prophylactic cefazolin in gastric bypass surgery. Surgery. 1981;90(2):426-432.
12. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet. 2010;375(9710):248-251.
13. Bratzler DW, Dellinger E P, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RS, Slain D, Steinberg J P, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283.
14. Edmiston CE, Krepel C, Kelly H, Larson J, Andris D, Hennen C, Nakeeb A, Wallace JR. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery. 2004;136(4):738-747.
15. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989;106(4):750-756.
16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349.
17. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-732.
18. Mehta U, Malone M, Alger S. Cefazolin use in clinically severe obese patients undergoing gastric restrictive surgery. Ann Pharmacother. 1995;29(9):935-936.
19. Ferraz AAB, Leão CS, Campos JM, Martins Filho E, Albuquerque AC, Ferraz EM. Proflaxia antimicrobiana na cirurgia bariátrica. Rev Col Bras Cir. 2007;34:73-77.
20. De Werra C, Di Micco R, Pilone V, Formato A, Montella E, Lambiase A, Cerbone D, Catania MR, Forestieri P. Serum in vivo and in vitro activity of single dose of ertapenem in surgical obese patients for prevention of SSIs. Obes Surg. 2013;23(7):911-919.